Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and Ewing Sarcoma

ecteinascidin 743 has been researched along with Ewing Sarcoma in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's10 (76.92)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boguslawski, EA; Bowman, MJ; Chasse, MH; Gedminas, JM; Grohar, PJ; Harlow, ML; Kitchen-Goosen, SM; Lessnick, SL; Madaj, ZB; Peck, AS; Rothbart, SB; Sorensen, KM; Taslim, C1
D'Incalci, M; Grohar, PJ; Helman, LJ; Mendoza, A; Pommier, Y; Segars, LE; Yeung, C1
Burdach, S1
Amaral, AT; D'Incalci, M; De Alava, E; Di Giandomenico, S; Frapolli, R; Garofalo, C; Hassan, AB; Malaguarnera, R; Manara, MC; Mancarella, C; Ordóñez, JL; Picci, P; Scotlandi, K; Sevillano, V; Uboldi, S1
Burdach, S; D'Incalci, M; DaPrada, GA; Fregoni, V; Grohar, PJ; Pavesi, L; Riccardi, A; Tancredi, R; Zambelli, A1
Alonso, D; Amaral, AT; Aracil, M; Carcaboso, AM; de Álava, E; del Carmen García-Macías, M; Fraile, S; Galmarini, CM; Herrero-Martín, D; Mayo-Iscar, A; Mora, J; Ordóñez, JL; Pascual-Pasto, G; Rodrigues, T; San-Segundo, L; Sevillano, V; Teodosio, C; Tirado, OM; Vila-Ubach, M1
Antony, S; Guirouilh-Barbat, J; Pommier, Y1
Chen, QR; Griffin, LB; Grohar, PJ; Helman, LJ; Khan, J; Khanna, C; Pommier, Y; Yeung, C1
Douer, D; Liu, SV; Tahbaz, A; Zneimer, S1
Adamson, PC; Baker, KS; Baruchel, S; Blaney, SM; Krailo, M; Lee-Scott, M; Pappo, A; Villaluna, D; Wu, B1
Grohar, PJ; Helman, LJ1
Benini, S; Cerisano, V; D'Incalci, M; Faircloth, G; Manara, MC; Mercuri, M; Perdichizzi, S; Picci, P; Reverter-Branchat, G; Scotlandi, K; Serra, M; Strammiello, R1
Astolfi, A; Bagnati, R; Benini, S; D'Incalci, M; Hattinger, CM; Manara, MC; Perdichizzi, S; Picci, P; Pierini, R; Scotlandi, K; Serra, M1

Reviews

1 review(s) available for ecteinascidin 743 and Ewing Sarcoma

ArticleYear
Prospects and challenges for the development of new therapies for Ewing sarcoma.
    Pharmacology & therapeutics, 2013, Volume: 137, Issue:2

    Topics: Antineoplastic Agents; Bone Neoplasms; Camptothecin; Clinical Trials as Topic; Dioxoles; Epigenesis, Genetic; Humans; Molecular Targeted Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Somatomedins; Tetrahydroisoquinolines; Trabectedin

2013

Trials

1 trial(s) available for ecteinascidin 743 and Ewing Sarcoma

ArticleYear
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4

    Topics: Adolescent; Adult; Algorithms; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Male; Medical Oncology; Pediatrics; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Societies, Medical; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult

2012

Other Studies

11 other study(ies) available for ecteinascidin 743 and Ewing Sarcoma

ArticleYear
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 06-01, Volume: 25, Issue:11

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chromatin; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Mice; Oncogene Proteins, Fusion; Protein Binding; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Trabectedin; Transcription Factors; Xenograft Model Antitumor Assays

2019
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Mar-01, Volume: 20, Issue:5

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dioxoles; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Irinotecan; Mice; Oncogene Proteins, Fusion; Phenotype; Proto-Oncogene Protein c-fli-1; RecQ Helicases; RNA Interference; RNA-Binding Protein EWS; RNA, Small Interfering; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Werner Syndrome Helicase; Xenograft Model Antitumor Assays

2014
Molecular precision chemotherapy: overcoming resistance to targeted therapies?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Mar-01, Volume: 20, Issue:5

    Topics: Animals; Antineoplastic Agents; Camptothecin; Dioxoles; DNA Damage; Female; Humans; Irinotecan; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin

2014
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-15, Volume: 21, Issue:6

    Topics: 12E7 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Caspase 7; Cell Line, Tumor; Dioxoles; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-fli-1; Pyrazines; Receptor, IGF Type 1; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin

2015
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Adult; Camptothecin; Dioxoles; Humans; Irinotecan; Male; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin

2015
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Oncotarget, 2015, 08-07, Volume: 6, Issue:22

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Dioxoles; DNA Damage; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays

2015
Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; DNA Damage; DNA Footprinting; DNA Repair; DNA Replication; Histones; Humans; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured

2009
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Child; DAX-1 Orphan Nuclear Receptor; Dioxoles; Europe; Gene Expression Regulation, Neoplastic; Humans; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; RNA-Binding Protein FUS; Sarcoma; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP

2011
Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
    Acta haematologica, 2011, Volume: 126, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; Etoposide; Fatal Outcome; Female; Gene Deletion; Gene Rearrangement; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Sarcoma, Ewing; Tetrahydroisoquinolines; Topoisomerase Inhibitors; Trabectedin; Young Adult

2011
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Differentiation; Dioxoles; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Isoquinolines; Nuclear Proteins; Osteosarcoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2002
The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
    International journal of oncology, 2005, Volume: 27, Issue:6

    Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cyclosporins; Dioxoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Inhibitory Concentration 50; Isoquinolines; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Receptor, IGF Type 1; Sarcoma, Ewing; Tetrahydroisoquinolines; Time Factors; Trabectedin

2005